SchizophreniaNCT00619437
Genetics of Schizophrenia
An observational study of Schizophrenia, run by Sheba Medical Center at 1 site in Israel.
Trial summary
Genetic etiology in schizophrenia is widely accepted. However, many chromosomal sites were shown to characterize the families of patients with schizophrenia. This is probably due to the high genetic heterogenity of this illness. Read more about this study
- Who is it for?
- Ages 18 to 78 years
- Conditions the study is for
- Schizophrenia
- How many people
- 100 participants
- Where
- 1 siteIsrael
- Study dates
- Apr 2008to Dec 2009
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 78 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: schizophrenia
Who may be able to join
- Age 18+;
- Meet DSM-IV criteria for Schizophrenia;
- At least one first-degree relative who Meet DSM-IV criteria for Schizophrenia;
- Can sign the informed consent form.
Who cannot join
- Patients suffering from terminal or incurabale disease;
- Minors, incompetents
Trial locations and contacts
1 site in 1 country.
Israel1 site
Sheba Medical Center
Tel HaShomer
Michael Bunzel, MD
Michael Bunzel, MD
About this study
Genetic etiology in schizophrenia is widely accepted. However, many chromosomal sites were shown to characterize the families of patients with schizophrenia. This is probably due to the high genetic heterogenity of this illness. Thus, it is important to investigate the genetic factor in relatively genetically homogenous populations. Many studies have indicate that Ashkenazy Jews show relative gentic homogenity. Indeed, the genes responsible for most Mendelian disorders of Jewish peoples have been identified. The study will apply genome-wide mutation screening methods to identify candidate allells in subjects of Ashkenazi Jewish ancestry with multiplex schizophrenia.
- Conditions
- Schizophrenia
- Keywords
- schizophrenia, genetics, family, multiplex, haplotypes
- Medical subject headings
- Schizophrenia
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Feb 2008 (estimated)
- Study startApr 2008
- Study completionDec 2009 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SchizophreniaStudies of the same condition, open and under way.
- More trials run by Sheba Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Family based
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sheba Medical Center
- Sponsor type
- Other government
- Investigators
- Michael Bunzel, MD, Study director, Psychiatric ward, Sheba Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00619437
- Sponsor's protocol ID
- SHEBA-07-4620-RG-CTIL
- Status last verified
- Feb 2008
- First submitted
- 10 Feb 2008
- Last updated
- 21 Feb 2008
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Feb 2008. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Genetics of Schizophrenia
- ClinicalTrials.gov ID
- NCT00619437
- Acronym / sponsor ID
- SHEBA-07-4620-RG-CTIL
- Conditions
- Schizophrenia
- Keywords
- schizophrenia, genetics, family, multiplex, haplotypes
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Sheba Medical CenterOther government
- Study start
- Apr 2008
- Study completion
- Dec 2009 (estimated)
- First posted
- 21 Feb 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Genetic etiology in schizophrenia is widely accepted. However, many chromosomal sites were shown to characterize the families of patients with schizophrenia. This is probably due to the high genetic heterogenity of this illness. Thus, it is important to investigate the genetic factor in relatively genetically homogenous populations. Many studies have indicate that Ashkenazy Jews show relative gentic homogenity. Indeed, the genes responsible for most Mendelian disorders of Jewish peoples have been identified. The study will apply genome-wide mutation screening methods to identify candidate allells in subjects of Ashkenazi Jewish ancestry with multiplex schizophrenia.
Study design
- Observational model
- Family based
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 78 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- schizophrenia
Key inclusion criteria (4 listed)
- Age 18+;
- Meet DSM-IV criteria for Schizophrenia;
- At least one first-degree relative who Meet DSM-IV criteria for Schizophrenia;
- Can sign the informed consent form.
Key exclusion criteria (2 listed)
- Patients suffering from terminal or incurabale disease;
- Minors, incompetents
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Feb 2008.
Related trials for Schizophrenia
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
Schizophrenia
Active, not recruitingPhase 2/3
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy
Suicidal Ideation, Major Depressive Disorder
RecruitingObservational study
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Schizophrenia
Not yet recruitingPhase 1
A Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable Schizophrenia
Schizophrenia
Not yet recruitingPhase 1
Phase I Trial of HHK101 in Patients With Schizophrenia
Schizophrenia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael Bunzel, MD study director
Psychiatric ward, Sheba Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Schizophrenia, run by Sheba Medical Center at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 21 Feb 2008. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Raz Gross, MD, MPH (972 3 530 3962, razg@gertner.health.gov.il), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Feb 2008.